The Human Variable 

Clinical trials for ME/CFS have consistently failed not because therapies were inherently ineffective, but because the system was never built for conditions like ME/CFS and related IACCs. FDA gold-standard trial design assumes predictable progression, uniform subtypes, and tolerance for interventions — none of which apply to ME/CFS The CYNAERA Thesis asserts that repurposed drugs can work for ME/CFS if trials account for post-exertional malaise (PEM),(MCAS), and POTS

The Va-IRI™ (Vaccination Immune Readiness Index) provides a structured 0–100 readiness score derived from common labs, symptom baselines, and patient function. Built on the STAIR Stable Method™ (Stabilization, Tolerance, And Immune Readiness), Va-IRI™ adapts low-and-slow principles pioneered by patients and refined through collaboration with leading researchers.

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating, multi-system neuroimmune disease on par with multiple sclerosis or congestive heart failure in severity, but for decades, it’s been sidelined by global health systems. Underdiagnosis, outdated clinical criteria, systemic bias, and institutional inertia have obscured its true scale. The result: tens of millions worldwide excluded from diagnosis, care, or recognition.

They called your symptoms anecdotal. They called your story rare. But inside your medical records, flare journals, and sleepless nights is the dataset no one bothered to decode. This isn’t just a blog post, it’s a call to reclaim your role as more than a subject. Inside, we share how a self-paced case study course helps patients and caregivers turn lived experience into lasting change.

A Nobel-scale leap, built outside the system. This isn’t just another CRISPR project. CYNAERA’s AI-powered gene editing platform was designed by a patient, for patients—modeling remission across millions of synthetic profiles to restore immune stability in infection-associated chronic conditions like Long COVID, ME/CFS, and MCAS. It cuts years off clinical trial timelines. It eliminates $5–10 million in early development costs. It’s scalable and ethical globally. AI meets bio

Infection-associated chronic conditions (IACCs) such as Long COVID, ME/CFS, POTS, and MCAS are not disparate diagnoses — they are systemic sequelae following immune injury. For too long, medicine has treated these illnesses as anomalies or mysteries, when in fact, they follow a biologically predictable pattern of dysregulation.